# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY ASSAY ONLY

I Background Information:

A 510(k) Number K232791   
B Applicant Beckman Coulter, Inc.

C Proprietary and Established Names Access Intact PTH

D Regulatory Information

<table><tr><td rowspan=1 colspan=1>ProductCode(s)</td><td rowspan=1 colspan=1>Classification</td><td rowspan=1 colspan=1>RegulationSection</td><td rowspan=1 colspan=1>Panel</td></tr><tr><td rowspan=1 colspan=1>CEW</td><td rowspan=1 colspan=1>Class II</td><td rowspan=1 colspan=1>21 CFR 862.1545 -Parathyroid HormoneTest System</td><td rowspan=1 colspan=1>CH - ClinicalChemistry</td></tr></table>

II Submission/Device Overview:

A Purpose for Submission: Modified device   
B Measurand: Parathyroid Hormone   
C Type of Test: Quantitative, Immunoenzymatic assay

III Intended Use/Indications for Use:

A Intended Use(s): See Indications for Use below.

# B Indication(s) for Use:

The Access Intact PTH assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of intact parathyroid hormone (parathyrin, PTH) levels in human serum and plasma using the Access Immunoassay Systems. It is indicated to aid in the differential diagnosis of hyperparathyroidism, hypoparathyroidism, or hypercalcemia of malignancy and can be used intraoperatively. Assay results should be used in conjunction with other clinical data to assist the clinician in making individual patient management decisions.

C Special Conditions for Use Statement(s): Rx - For Prescription Use Only   
D Special Instrument Requirements: DxI 9000 Access Immunoassay Analyzer

IV Device/System Characteristics:

A Device Description:

The device consists of the components described below.

Access Intact PTH (iPTH) Reagent Pack:

R1a: $3 . 2 5 \mathrm { m L }$ , Paramagnetic particles coated with goat anti-PTH antibody   
suspended in TRIS buffered saline with bovine serum albumin (BSA), surfactant, $< 0 . 1 \%$ sodium azide, $0 . 1 \%$ ProClin 300.   
R1b: $3 . 1 \mathrm { m L }$ , TRIS buffered saline with block ACE, protein (mouse, goat),   
surfactant, $< 0 . 1 \%$ sodium azide, $0 . 1 \%$ ProClin 300.   
R1c: $3 . 1 \mathrm { m L }$ , Mouse monoclonal anti-PTH alkaline phosphatase conjugate in   
ACES buffered saline with BSA, surfactant, $< 0 . 1 \%$ sodium azide, $0 . 1 \%$ ProClin 300.

# Materials Required but Not Provided

The Beckman Coulter Access Intact PTH (iPTH) Assay is designed for use in conjunction with the following products:

• Access Intact PTH Calibrators • Lumi-Phos PRO Substrate • Unicell Dxl Wash Buffer II Access Sample Diluent A

# B Principle of Operation:

The Access Intact PTH assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of intact parathyroid hormone (parathyrin, PTH) levels in human serum and plasma using the Access Immunoassay Systems. The assay principle uses a two-site immunoenzymatic (“sandwich”) assay, where a sample $( 5 5 ~ \mu \mathrm { L } )$ is added to a reaction vessel, along with a monoclonal anti-PTH antibody conjugated to alkaline phosphatase, TRIS buffered saline with proteins and paramagnetic particles coated with a goat polyclonal anti-PTH antibody. Samples may be run in one of two modes: routine mode $( \leq 3 0$ minutes from start of sample pipetting to test result) and intraoperative mode $\leq 1 5$ minutes from start of sample pipetting to test result). After incubation, materials bound to the solid phase are held in a magnetic field while unbound materials are washed away. Then, the chemiluminescent substrate is added to the vessel and light generated by the reaction is measured with a luminometer. The light production is directly proportional to the concentration of analyte in the sample. Analyte concentration is automatically determined from a stored calibration.

V Substantial Equivalence Information:

A Predicate Device Name(s): Access Intact PTH

B Predicate 510(k) Number(s): K061190

# C Comparison with Predicate(s):

<table><tr><td rowspan=1 colspan=1>Device &amp; PredicateDevice(s):</td><td rowspan=1 colspan=1>K232791</td><td rowspan=1 colspan=1>K061190</td></tr><tr><td rowspan=1 colspan=1>Device Trade Name</td><td rowspan=1 colspan=1>Access Intact PTHassay</td><td rowspan=1 colspan=1>Access Intact PTHassay</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Similarities</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Intended Use/IndicationsFor Use</td><td rowspan=1 colspan=1>Quantitativedetermination of intactparathyroid hormone(parathyrin, PTH) levelsin human serum andplasma. It is indicatedto aid in the differentialdiagnosis ofhyperparathyroidism,hypoparathyroidism, orhypercalcemia ofmalignancy and can beused intraoperatively.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample type</td><td rowspan=1 colspan=1>Serum or Plasma(Heparin and EDTA)</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>General DeviceCharacteristic Differences</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Measuring range</td><td rowspan=1 colspan=1>1.7 - 3,500 pg/mL</td><td rowspan=1 colspan=1>1 - 3,500 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>Lumi-Phos PROSubstrate</td><td rowspan=1 colspan=1>Access Substrate</td></tr><tr><td rowspan=1 colspan=1>Analyzer platform</td><td rowspan=1 colspan=1>DxI 9000 AccessImmunoassay Analyzer</td><td rowspan=1 colspan=1>Access 2 Immunoassaysystem</td></tr></table>

# VI Standards/Guidance Documents Referenced:

Clinical & Laboratory Standards Institute (CLSI) EP05-A3 Evaluation of Precision of   
Quantitative Measurement Procedures; Approved Guideline - Third Edition   
CLSI EP09c 3rd Edition Measurement Procedure Comparison and Bias Estimation Using   
Patient Samples   
CLSI EP17-A2 Evaluation of Detection Capability for Clinical Laboratory Measurement   
Procedures; Approved Guideline - Second Edition   
CLSI EP06-2nd Edition Evaluation of the Linearity of Quantitative Measurement Procedures   
A Statistical Approach; Approved Guideline

# VII Performance Characteristics (if/when applicable):

A Analytical Performance:

1. Precision/Reproducibility:

Routine Mode:

A precision study was performed in accordance with CLSI EP05-A3. Five serum samples with PTH concentrations spanning the analytical range were tested using three reagent lots on three DxI 9000 Access Immunoassay Analyzers. Samples were assayed in duplicate using 2 runs per day over 20 days for a total of 80 replicates per sample per lot. Results from multiple lots were similar. Within-run (repeatability), within-lab (total), between-run, and between-day precision results for a representative reagent lot on a single instrument are summarized below:

<table><tr><td rowspan=1 colspan=3>Concentration (pg/mL)</td><td rowspan=1 colspan=2>Repeatability(Within-run)</td><td rowspan=1 colspan=2>Between-run</td><td rowspan=1 colspan=2>Between-day</td><td rowspan=1 colspan=2>Within- Laboratory(Total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Meanpg/mL</td><td rowspan=1 colspan=1>SDpg/mL</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SDpg/mL</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SDpg/mL</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SDpg/mL</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>SAMPLE1</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.10</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>0.41</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.46</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>SAMPLE2</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>0.40</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>0.48</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.79</td><td rowspan=1 colspan=1>6.5</td></tr><tr><td rowspan=1 colspan=1>SAMPLE3</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>89</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>SAMPLE4</td><td rowspan=1 colspan=1>86</td><td rowspan=1 colspan=1>1369</td><td rowspan=1 colspan=1>44.2</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>15.4</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>18.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>50.3</td><td rowspan=1 colspan=1>3.7</td></tr><tr><td rowspan=1 colspan=1>SAMPLE5</td><td rowspan=1 colspan=1>84</td><td rowspan=1 colspan=1>2449</td><td rowspan=1 colspan=1>48.9</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>14.2</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>40.8</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>65.2</td><td rowspan=1 colspan=1>2.7</td></tr></table>

Intraoperative Mode:

A precision study was performed in accordance with CLSI EP05-A3. Seven serum samples were tested using three reagent lots on three DxI 9000 Access Immunoassay Analyzers. Seven serum samples with PTH concentrations spanning the analytical range were assayed in duplicate using 2 runs per day over 20 days for a total of 80 replicates per sample per lot. Results from multiple lots were similar. Within-run (repeatability), within-lab (total), betweenrun, and between-day precision results for a representative reagent lot on a single instrument are summarized below:

<table><tr><td rowspan=1 colspan=3>Concentration (pg/mL)</td><td rowspan=1 colspan=2>Repeatability(Within-run)</td><td rowspan=1 colspan=2>Between-run</td><td rowspan=1 colspan=2>Between-day</td><td rowspan=1 colspan=2>Within- Laboratory(Total)</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Meanpg/mL</td><td rowspan=1 colspan=1>SDpg/mL</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SDpg/mL</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SDpg/mL</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SDpg/mL</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>SAMPLE1</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.15</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>0.13</td><td rowspan=1 colspan=1>7.3</td><td rowspan=1 colspan=1>0.12</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>0.23</td><td rowspan=1 colspan=1>13.2</td></tr><tr><td rowspan=1 colspan=1>SAMPLE2</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.27</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>0.19</td><td rowspan=1 colspan=1>2.9</td><td rowspan=1 colspan=1>0.33</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>SAMPLE3</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>2.7</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>4.8</td></tr><tr><td rowspan=1 colspan=1>SAMPLE4</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>34</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>4.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>4.2</td></tr><tr><td rowspan=1 colspan=1>SAMPLE5</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>169</td><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>6.8</td><td rowspan=1 colspan=1>4.0</td></tr><tr><td rowspan=1 colspan=1>SAMPLE6</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>1014</td><td rowspan=1 colspan=1>41.7</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>13.1</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>43.8</td><td rowspan=1 colspan=1>4.3</td></tr><tr><td rowspan=1 colspan=1>SAMPLE7</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>2542</td><td rowspan=1 colspan=1>72.3</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>41.7</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>83.5</td><td rowspan=1 colspan=1>3.3</td></tr></table>

# 2. Linearity:

Linearity studies were performed using serum samples across the assay measuring range to evaluate the linearity of the Access Intact PTH assay on the DxI 9000 Access Immunoassay Analyzer in accordance with the CLSI Guideline EP06-Ed2. The data was analyzed using a weighted linear regression model. The deviation from linearity for the routine mode did not exceed $5 \%$ and for the intraoperative mode, did not exceed $8 \%$ .

The results of these linearity studies support that the Access Intact PTH assay is linear on the $\operatorname { D x I } 9 0 0 0$ Access Immunoassay Analyzer throughout the proposed analytical measuring interval of $1 . 7 - 3 , 5 0 0 \ : \mathrm { p g / m L }$ .

# 3. Analytical Specificity/Interference:

Interference was previously established in K061190. The sponsor provided information to support that biotin up to $3 5 0 0 ~ \mathrm { n g / m L }$ does not interfere with the test.

4. Assay Reportable Range: See Linearity section above.

5. Traceability, Stability, Expected Values (Controls, Calibrators, or Methods): The Access Intact PTH assay is traceable to international WHO standard 79/500.

6. Detection Limit:

Limit of Blank (LoB), Limit of Detection (LoD), and Limit of Quantitation (LoQ) were evaluated based on the CLSI guideline EP17-A2. The LoQ was defined as the lowest concentration of analyte which has imprecision less than or equal to $20 \%$ CV.

The LoB, LoD, and LoQ results are summarized below:

<table><tr><td rowspan=1 colspan=1>Mode</td><td rowspan=1 colspan=1>LoB</td><td rowspan=1 colspan=1>LoD</td><td rowspan=1 colspan=1>LoQ</td></tr><tr><td rowspan=1 colspan=1>Routine</td><td rowspan=1 colspan=1>0.5 pg/mL</td><td rowspan=1 colspan=1>0.7 pg/mL</td><td rowspan=1 colspan=1>0.7 pg/mL</td></tr><tr><td rowspan=1 colspan=1>Intraoperative</td><td rowspan=1 colspan=1>0.5 pg/mL</td><td rowspan=1 colspan=1>0.8 pg/mL</td><td rowspan=1 colspan=1>0.8 pg/mL</td></tr></table>

7. Assay Cut-Off:

Not applicable.

# B Comparison Studies:

1. Method Comparison with Predicate Device:

Routine Mode:

A method comparison study was completed to compare the candidate device to the predicate device in routine mode in accordance with CLSI EP09c $3 ^ { \mathrm { r d } }$ Edition. Weighted Deming analysis was performed, and the results are summarized below.

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Sample rangetested (pg/ml)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept(pg/mL)</td><td rowspan=1 colspan=1>CorrelationCoefficient (r)</td></tr><tr><td rowspan=1 colspan=1>144</td><td rowspan=1 colspan=1>1.9 - 3233</td><td rowspan=1 colspan=1>0.97</td><td rowspan=1 colspan=1>-0.23</td><td rowspan=1 colspan=1>1.00</td></tr></table>

Intraoperative Mode:

A method comparison study was completed to compare the Access PTH Intraoperative mode (PTH-IO) assay on DxI 9000 Access Immunoassay Analyzer to the predicate device, the Access PTH assay (Routine mode) on the Access 2 Immunoassay System in accordance with CLSI $\operatorname { E P 0 9 c }$ $3 ^ { \mathrm { r d } }$ Edition. Weighted Deming analysis was performed, and the results are summarized below.

<table><tr><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Sample rangetested (pg/ml)</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>Intercept(pg/mL)</td><td rowspan=1 colspan=1>CorrelationCoefficient (r)</td></tr><tr><td rowspan=1 colspan=1>116</td><td rowspan=1 colspan=1>2.1-3275</td><td rowspan=1 colspan=1>1.02</td><td rowspan=1 colspan=1>-0.081</td><td rowspan=1 colspan=1>0.99</td></tr></table>

A supplemental study was performed comparing the performance of the Access PTH assay in the Intraoperative mode on the DxI 9000 Access Immunoassay Analyzer to the Access 2 Immunoassay system. The results demonstrated that the performance of the device was not impacted by modifications to the device.

2. Matrix Comparison: Previously established in K061190.

# C Clinical Studies:

1. Clinical Sensitivity: Not applicable.

2. Clinical Specificity: Not applicable.

3. Other Clinical Supportive Data (When 1. and 2. Are Not Applicable): Not applicable.

D Clinical Cut-Off: Not applicable.

# E Expected Values/Reference Range:

Data establishing the reference range for the Access Intact PTH assay was previously reviewed in K061190.

# VIII Proposed Labeling:

The labeling does support the finding of substantial equivalence for this device.

# IX Conclusion:

The submitted information in this premarket notification is complete and does support a substantial equivalence decision.